BioMarin Pharma (BMRN.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec23

Truist Financial's Analyst Reiterates Buy Rating on Bimatric Pharma

12:26

BioMarin Pharmaceuticals to acquire Amicus Therapeutics for $4.8 billion

03:32

Dec22

Bamaline Pharmaceuticals Ceases Development of BMN 349 for AATD-related Liver Disease

14:37

Dec3

HSBC Increased Holdings in Bausch Health Companies

09:22

Nov21

Eagle Health Investments LP reduces holdings in Bausch Health Companies Inc.

09:49

Nov9

Campbell & CO Increases Holdings in BioMarin Pharmaceutical Inc.

09:34

Schedules & Filings

Schedules

Filings

Oct27

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 776.13 M, Net Income -30.74 M, EPS -0.16

BioMarin Pharmaceutical Inc. (BMRN.US) Q3 2025 Earnings Conference Call

Aug4

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 825.41 M, Net Income 240.53 M, EPS 1.2297

BioMarin Pharmaceutical Inc. (BMRN.US) Q2 2025 Earnings Conference Call

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 745.15 M, Net Income 185.69 M, EPS 0.9544

BioMarin Pharmaceutical Inc. (BMRN.US) Q1 2025 Earnings Conference Call

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change